OOIR: Observatory of International Research

Papers

(The H4-Index of Journal of Neurology Neurosurgery and Psychiatry is 48. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-04-01 to 2024-04-01.)

Article	Citations
Characteristics of ischaemic stroke associated with COVID-19	524
Parkinson’s disease: etiopathogenesis and treatment	454
Evidence-based prevention of Alzheimer's disease: systematic review and meta-analysis of 243 observational prospective studies and 153 randomised controlled trials	248
Autoimmune encephalitis: proposed best practice recommendations for diagnosis and acute management	221
Status of SARS-CoV-2 in cerebrospinal fluid of patients with COVID-19 and stroke	189
TDP-43 proteinopathies: a new wave of neurodegenerative diseases	166
Serum neuronal exosomes predict and differentiate Parkinson’s disease from atypical parkinsonism	143
Guillain-Barré syndrome and COVID-19: an observational multicentre study from two Italian hotspot regions	117
Psychological impact on women health workers involved in COVID-19 outbreak in Wuhan: a cross-sectional study	112
Guillain-Barré syndrome in SARS-CoV-2 infection: an instant systematic review of the first six months of pandemic	110
Pattern of cognitive deficits in severe COVID-19	99
Nusinersen safety and effects on motor function in adult spinal muscular atrophy type 2 and 3	94
Central nervous system complications associated with immune checkpoint inhibitors	90
Diagnostic and prognostic value of serum NfL and p-Tau₁₈₁in frontotemporal lobar degeneration	89
Clinical spectrum of high-titre GAD65 antibodies	82
The future of neuroprotection in stroke	81
Postinfectious brainstem encephalitis associated with SARS-CoV-2	73
COVID-19–associated acute necrotising encephalopathy successfully treated with steroids and polyvalent immunoglobulin with unusual IgG targeting the cerebral fibre network	70
Cognitive effects and acceptability of non-invasive brain stimulation on Alzheimer’s disease and mild cognitive impairment: a component network meta-analysis	69
Value of systematic genetic screening of patients with amyotrophic lateral sclerosis	68
Occupational therapy consensus recommendations for functional neurological disorder	67
Neuralgic amyotrophy: a paradigm shift in diagnosis and treatment	66
Neurological manifestations of the coronavirus (SARS-CoV-2) pandemic 2019–2020	65
Autoimmune encephalitis: proposed recommendations for symptomatic and long-term management	65
Complete Epstein-Barr virus seropositivity in a large cohort of patients with early multiple sclerosis	64

Diagnostic and therapeutic aspects of hemiplegic migraine	63
Differential levels of plasma biomarkers of neurodegeneration in Lewy body dementia, Alzheimer’s disease, frontotemporal dementia and progressive supranuclear palsy	63
Characteristics and outcomes of COVID-19 associated stroke: a UK multicentre case-control study	62
Fluid biomarkers in frontotemporal dementia: past, present and future	61
Decade of progress in motor functional neurological disorder: continuing the momentum	61
Parkinson’s disease determinants, prediction and gene–environment interactions in the UK Biobank	60
Advances in the management of glioblastoma	59
Defining causality in COVID-19 and neurological disorders	58
Cerebral microbleeds: from depiction to interpretation	57
Ischaemic stroke as a presenting feature of ChAdOx1 nCoV-19 vaccine-induced immune thrombotic thrombocytopenia	56
Prevalence and incidence of neuromyelitis optica spectrum disorder, aquaporin-4 antibody-positive NMOSD and MOG antibody-positive disease in Oxfordshire, UK	55
Neuronal pentraxin 2: a synapse-derived CSF biomarker in genetic frontotemporal dementia	54
Brainstem and cerebellar involvement in MOG-IgG-associated disorder versus aquaporin-4-IgG and MS	53
Management of functional communication, swallowing, cough and related disorders: consensus recommendations for speech and language therapy	52
Anti-CASPR2 clinical phenotypes correlate with HLA and immunological features	52
Performance validity test failure in clinical populations—a systematic review	51
Blood-based high sensitivity measurements of beta-amyloid and phosphorylated tau as biomarkers of Alzheimer’s disease: a focused review on recent advances	51
Clinical trials in REM sleep behavioural disorder: challenges and opportunities	50
Neurology and neuropsychiatry of COVID-19: a systematic review and meta-analysis of the early literature reveals frequent CNS manifestations and key eme	49
Anti-CD20 therapies decrease humoral immune response to SARS-CoV-2 in patients with multiple sclerosis or neuromyelitis optica spectrum disorders	48
Neurology in the time of COVID-19	48
Untargeted metabolomics yields insight into ALS disease mechanisms	48
LGI1 antibody encephalitis: acute treatment comparisons and outcome	48